Researchers from the University of Nottingham and RDM assessed the suitability of desmopressin to be used in larger trials to help reduce the number of people who die or are disabled after intracerebral haemorrhage. The results from the DASH trial, which was funded by the National Institute for Health and Care Research (NIHR), have been published in The Lancet Neurology.
Approximately three million deaths each year worldwide are due to spontaneous intracerebral haemorrhage, and there is currently no proven effective drug treatment. Researchers estimate that two-thirds of survivors are left dependent on others and a quarter of patients were taking antiplatelet drugs at the time of incident.
Read the full story on the Radcliffe Department of Medicine website.